Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3053102 · 1 trial · 1 indication
A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| Arm | Type | Description |
|---|---|---|
| LY3053102 | EXPERIMENTAL | A single 2-, 7-, 20-, 50-, 150-, or 405-milligrams (mg) dose of LY3053102 was subcutaneously administered to newly randomized participants in 6 escalating dose level cohorts. The dose was escalated based on the safety results over at least a 7-day evaluation period postdose. The dose escalation occurred over 13 weeks proceeding according to tolerability at each dose level. |
| Placebo | PLACEBO_COMPARATOR | A single dose of LY3053102-matching placebo was administered subcutaneously to 1 newly randomized participant in each LY3053102-dose level cohort over 13 weeks. |
| Name | Type | Description |
|---|---|---|
| LY3053102 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Normal blood pressure * Female participants were not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause * Had a body mass index (BMI) of 18.5 to 40.0 kilograms per square meter (kg/m\^2), inclusive, ...
LY3053102 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in early clinical development. The only completed trial evaluated its effects in healthy participants to assess safety and tolerability.
The molecular target of LY3053102 has not been disclosed. The drug is a small molecule, but its specific biological target is not publicly available from the clinical trial information provided.
LY3053102 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker LLY. The company sponsored the clinical trial of this investigational drug.
LY3053102 is in Phase 1 clinical development. The single trial listed for this drug is a Phase 1 study that has been completed. The drug remains investigational and has not received regulatory approval.
LY3053102 has one completed Phase 1 trial, NCT01736241, titled 'A Study of LY3053102 in Healthy Participants.' This randomized, double-blind, placebo-controlled study enrolled 41 healthy volunteers in Singapore and has been completed.
No alternative names for LY3053102 have been disclosed. The drug is identified only by its code name LY3053102 in the clinical trial information.